World’s 1st Nanomedicine CDMO
& Clinical-Phase Fill-Finish CMO

We develop and scale nanoparticle drug substance, and fill clinical-phase batches in a purpose-built sterile suite aligned with the current EU GMP Annex 1 — one partner, one hand-off avoided.

About

OmniParticles

We specialize in nanoparticle medicines on the drug substance side, and provide aseptic fill-finish across modalities for clinical supply.

Two Services, One Quality System

Nanoparticle
Drug Substance

CDMO

+

Aseptic Sterile Drug Product

CMO

Custom Synthesis

Autosampler loaded with sample vials for biopharmaceutical analysis at Omniparticles CDMO laboratory

More

We provide CDMO service on nanomedicine in the early stages of development by tailoring types of nanoparticles, chemical composition, ratio, etc. for specific target diseases and desired therapeutic effect.

CDMO Case Highlights

Stainless steel pharmaceutical processing vessel with pressure gauge and valves in a GMP-compliant CDMO facility

More

has developed world’s first FDA IND approved anti-inflammatory cerium oxide nanomedicine for acute AND chronic diseases (from critical to degenerative conditions).

OmniParticles

Aseptic Fill-Finish

More

Aseptic fill-finish for preclinical and Phase I/II/III clinical supply. We fill batches of 2,000–5,000 vials under Grade A conditions in open RABS, with a fully single-use product-contact train.

GMP-compliant Facility

State-of-the-art biopharmaceutical laboratory with GMP-compliant equipment and large-scale research facilities

More

Our drug substance CDMO is optimized for early-stage nanomedicine development, and our GMP-compliant facility enables in-house drug substance manufacturing and aseptic fill-finish.

One Partner from Drug Substance to Drug Product

Nanoparticle drug substance development and GMP manufacturing, with aseptic fill-finish for clinical-phase supply

About

OmniParticles

We specialize in nanoparticle medicines on the drug substance side, and provide aseptic fill-finish across modalities for clinical supply.

Two Services, One Quality System

Custom Synthesis

We provide CDMO service on nanomedicine in the early stages of development by tailoring types of nanoparticles, chemical composition, ratio, etc. for specific target diseases and desired therapeutic effect.

CDMO Case Highlights​

has developed world’s first FDA IND approved anti-inflammatory cerium oxide nanomedicine for acute AND chronic diseases (from critical to degenerative conditions).

OmniParticles

Aseptic Fill-Finish

Aseptic fill-finish for preclinical and Phase I/II/III clinical supply. We fill batches of 2,000–5,000 vials under Grade A conditions in open RABS, with a fully single-use product-contact train.

GMP-compliant Facility

Our drug substance CDMO is optimized for early-stage nanomedicine development, and our GMP-compliant facility enables in-house drug substance manufacturing and aseptic fill-finish.

CDMO Case Highlights